Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Sumitomo subsidiary flashes new way of treating schizophrenia in PhII trial
6 years ago
Ex-GSK chief Andrew Witty summoned back to the frontlines of vaccine development at embattled WHO
6 years ago
Gilead takes a hit after a closely-watched Covid-19 trial of remdesivir is quietly terminated, raising fresh doubts
6 years ago
Coronavirus
As GSK and Sanofi promise to produce a Covid-19 vaccine at Indy 500 speed, some experts start to push back on timelines
6 years ago
Coronavirus
Micro-cap Mei Pharma lands $100M upfront on beleaguered PI3K pathway
6 years ago
Deals
Ploughing through a crowded PD-(L)1 market, BeiGene loads up on promising lung cancer data
6 years ago
China
Pharma
Moderna's mission to spearhead a revolution in vaccine R&D comes center stage today as the world faces a crucial turning point
6 years ago
Coronavirus
Creative or unethical? Researchers’ Covid-19 GoFundMe campaign spurs critics
6 years ago
Coronavirus
In Focus
Q&A: Analyst-turned biotech exec-turned analyst reads the biotech Q1 tea leaves
6 years ago
People
Pharma
AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy
6 years ago
Judge slaps enhanced damages on Gilead/Kite for ‘willful’ patent violation, boosting award to a blockbuster $1.2B — with the meter running
6 years ago
A small remdesivir study with lots of shortcomings suggests it may be working against Covid-19 — and 1 analyst forecasts mid-May rollout
6 years ago
Coronavirus
Natural killers are coming for Covid-19 and the therapy, experts say, could make things worse
6 years ago
Coronavirus
In Focus
Tango Therapeutics nabs $60M in CRISPR-based hunt for hidden cancer genes
6 years ago
Financing
Did Gilead just lower the bar on crucial remdesivir trials for Covid-19? Switching endpoints, amping up trial size stir analysts' fears — and hopes
6 years ago
Coronavirus
Zai Lab finds latest target in Regeneron’s bispecific, paying up to $190M for Chinese rights
6 years ago
Deals
Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
6 years ago
FDA+
Blasted by PhIII failure, a struggling Sage axes 340 staffers and bunkers down to survive the storm
6 years ago
Pivotal failure crumbles stock for Michigan’s once-promising Millendo
6 years ago
Ready to declare a definitive comeback in two months, Immunomedics stops PhIII early, recruits new CEO
6 years ago
People
Small molecules, biologics and now gene therapies: Germany's Evotec adds another feather to its R&D cap
6 years ago
A pair of PhIII failures spells last rites for Menlo’s once-promising Merck drug
6 years ago
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
6 years ago
Deals
GSK's Hal Barron buys a $250M stake in George Scangos' Vir and makes a beeline to the clinic with Covid-19 antibodies
6 years ago
Deals
Coronavirus
First page
Previous page
205
206
207
208
209
210
211
Next page
Last page